Clene Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
CLNN · Price history
Price at last available close
$4.03
−$0.07 (-1.71%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Clene Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
How they make money
Clene Inc. is a late clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings, debt facilities, and potential future licensing or commercialization of its proprietary nanotherapeutic drug candidates.
Products & services
Clene develops metallic nanocrystal therapeutic candidates, with its lead candidate being CNM-Au8, an investigational nanotherapeutic designed to improve neuronal function and energy metabolism for neurodegenerative diseases.
Brands & revenue mix
Lead nanotherapeutic drug candidate for neurodegenerative diseases.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes third-party contract manufacturing organizations for the production and formulation of its drug candidates.Source
Competitors
- Major pharmaceutical companies — Global entities with significant resources developing treatments for neurological diseases.Source
- Specialty pharmaceutical companies — Firms focused on niche therapeutic areas including neurodegeneration.Source
- Biotechnology companies — Companies worldwide competing in the development of new drug candidates for neurological disorders.Source
Strengths
- Proprietary nanotherapeutic platform technologySource
Company-specific research
Questions worth answering for CLNN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving CLNN's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How long can CLNN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is CLNN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for CLNN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CLNN's current valuation?
Essential Investment Snapshot
Market Cap
$57.3M
P/E Ratio
-1.1
EPS
$-3.55
52-Week High
$13.50
52-Week Low
$3.25
Beta
0.95
Analyst Target
$50.00
Shares Outstanding
9.9M
Total Debt
$22.3M
Dividend
No current dividend
Liquidation Value / Share
$-2.51
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CLNN
Detected from reported data — verify before acting.Severe debt stress
Negative shareholder equity • Total debt is at least one year of revenue • Interest coverage is below 2x • Free cash flow is negative
Community Sentiment
0 active · 0 total callsNo personal call yet on CLNN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary nanotherapeutic platform technology.
Potential downside factors
- −Debt risk (severe): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Interest coverage is below 2x.
- −Free cash flow is negative.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$4.03
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $197K | $200K | $342K | $654K | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $414K | $43K | $70K | $121K | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | -$217K | $157K | $272K | $533K | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $12.8M | $14.0M | $20.1M | $26.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $7.6M | $9.2M | $13.3M | $14.4M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $20.1M | $23.2M | $33.4M | $41.1M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$27.8M | -$22.0M | -$33.7M | -$43.2M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$20.3M | -$23.1M | -$33.1M | -$40.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $2.9M | $2.7M | $4.1M | $4.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$39.5M | -$26.2M | -$39.4M | -$49.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$39.5M | -$26.2M | -$39.4M | -$49.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.55 | $-2.65 | $-5.67 | $-9.43 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 12.38M | 9.86M | 6.95M | 5.25M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 12.38M | 9.86M | 6.95M | 5.25M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$90000
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.08
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+7.2%
Cash Change
+32.8%
Margin Change
+12562.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 233.3%. EPS increased 38.5%. Cash increased 32.8%. Total debt increased 7.2%. Net income margin improved by 12562.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS
Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision
Clene Inc. (NASDAQ:CLNN) Receives Average Recommendation of “Moderate Buy” from Brokerages
Clene to Present at Upcoming Investor Conferences
Rumor Mill · CLNN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial